GeNeuro: financial information and business update for the second quarter 2020
Geneva, Switzerland, July 23, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2020 second quarter cash position and issued a business update. https://geneuro.ch/data/news/2020.07.23-GeNeuro-PR-Q2-2020-EN-Final.pdf